● AI Equity Research · Healthcare

Alphatec Holdings, Inc. (ATEC)

AI stock analysis · Medical Devices · Last analyzed Aug 17, 2026

Compass Score

3.0/5

Call

Hold

Price

$9.79

AI Target

$15.79 +61.2%

AI Analyst Summary

Alphatec Holdings is a high-growth spine surgery technology company leveraging its proprietary procedural approach and EOS imaging platform to take share in a large, underpenetrated market — driving 15.1% revenue growth and a compelling forward P/E of just 16.4x. With a PEG ratio of 0.48 and unanimous analyst buy ratings (14 of 14), the stock appears materially undervalued relative to its durable growth profile. The primary risk is the company's current loss-making status, which leaves it dependent on continued revenue momentum and external financing conditions to reach profitability.

Catalysts

Continued spine surgery volume growth and market share gains driven by ATEC's proprietary SafeOp neural monitoring and EOS imaging platform, with Q3/Q4 revenue prints expected to sustain or accelerate the 15%+ growth rate.
Pathway to GAAP profitability as operating leverage scales — a re-rating event that could compress the forward P/E discount and attract a broader institutional investor base.
Potential new product launches or procedural expansions in the lateral and cervical spine segments, which could expand the total addressable market and drive incremental revenue beats in upcoming quarters.

Fundamentals

Pe N/A (loss-making) · 2.0/5

No trailing P/E available as the company is currently loss-making. However, the forward P/E of 16.4x is reasonable for a high-growth medical device company, suggesting a credible path to profitability that partially offsets the concern.

Peg 0.48 · 5.0/5

PEG of 0.48 is well below 1.0, indicating the stock is significantly undervalued relative to its growth trajectory. This is a strong positive signal for a healthcare/medical device name with durable revenue momentum.

Analyst Rating Strong Buy consensus (1.2) · 5.0/5

Unanimous bullish conviction: 14 Buy ratings, 0 Hold, 0 Sell. A consensus rating of 1.2 on the inverted scale reflects exceptional analyst confidence, well above the threshold for a score of 5.

Earnings Trend Revenue +15.1% YoY; EPS trend improving · 4.0/5

Revenue growth of 15.1% YoY is strong for the medical devices sector and has been consistent. Earnings-per-share data is limited given the loss-making status, but the directional trend toward profitability (forward P/E of 16.4x) and a perfect 4-of-4 EPS beat rate support a constructive earnings trajectory.

Price Target Beat 4 of 4 quarters beat · 4.0/5

The company has beaten EPS estimates in all 4 of the last 4 reported quarters. With only 4 quarters of history available, a score of 4 is applied per guidelines — a strong indicator of consistent execution and management's ability to deliver against expectations.

Management Consistent execution with strong analyst confidence · 4.0/5

A 4-of-4 EPS beat record, unanimous analyst buy ratings, and sustained double-digit revenue growth signal a management team executing reliably on its growth plan. Capital allocation appears focused on scaling the business toward profitability, though loss-making status warrants slight conservatism.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.